drugset / Trial / NCT00000594

NHLBI Type II Coronary Intervention Study

NCT00000594

RandomizedDouble-blindPrevention

Summary

To determine whether lowering of cholesterol with cholestyramine in a population with Type II hyperlipidemia led to a decreased rate of progression (a regression of coronary artery disease) as demonstrated by death, myocardial infarction, or progression of disease on angiography.

Timeline

Start
1971-11
Primary completion
Completion
1976-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cholestyramine Other / unclassified